Antiviral

/ /

How Merck Canada is responding to the COVID-19 pandemic

We are inspired by a shared vision and mission to save and improve lives and have been committed to fighting against the COVID-19 pandemic from the beginning. This includes both our investment in research that could help protect Canadians from this pandemic, as well as supporting the communities in which we work and live in.

Investing in COVID-19 therapies

Vaccines are playing a crucial role in helping prevent the spread and seriousness of cases of COVID-19, but they alone may not eliminate the virus. To help keep Canadians safe, more tools and treatments are urgently needed to fight COVID-19, which is why we are investing in research for potential treatment approaches that could have a meaningful and direct impact on patients suffering with COVID-19.

“As the need for medicines and vaccines have continued to evolve, we have worked to deploy our expertise and resources where they would have the greatest impact on the COVID-19 pandemic.”

Dr. Gretty Deutsch, Vice President, Medical Affairs & Country Medical Director at Merck Canada

As well, our commitment to keep improving the lives of Canadians means we know when we must lend a hand and collaborate across borders and companies. That’s why we have entered a partnership to support the manufacturing and supply of Johnson & Johnson’s COVID-19 vaccine.

“Investment in vaccines and medicines will help ensure Canadians’ health and economic security. Unfortunately, viral outbreaks will continue to happen, and we need a different kind of preparedness, which will take political and industry leadership.”

Marwan Akar, President and Managing Director of Merck Canada

Investing in our communities

We have always helped empower the communities we have the privilege to work with. During the pandemic we have invested funds in numerous local Canadian organizations that work on the frontlines. We have also strategically invested funds to ensure that personal protective equipment (PPE) has been available where it has been needed most.

How we are showing up:

•$100,000 contribution for the purchase of personal protective equipment (PPE) through Innovative Medicines Canada for distribution across the country
•$200,000 in sponsorships for patient associations to support patient programs to ensure continued care for cancer patients, including support for diagnosis and treatment
•$100,000 in financial support for relief efforts for vulnerable populations to various charitable organizations across Canada, including the Canadian Red Cross, Food Banks Canada, and the United Way
•Encouragement of employees to support their communities, including allowing medically trained employees to volunteer their time to aid in our healthcare system where needed.

CA-NON-01600

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.